{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "ad35add2",
   "metadata": {},
   "source": [
    "# Agent Case Study with OpenAI SDK\n",
    "\n",
    "This notebook shows **with vs without** using the same user prompt:\n",
    "- Direct Agent (no planning loop)\n",
    "- Planning Agent (Planner -> Executor -> Final)\n",
    "\n",
    "Also includes Tool and Memory demos."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c8e148be",
   "metadata": {},
   "source": [
    "## 1) Install"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a77d8b0e",
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip -q install openai python-dotenv chromadb"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "6fb42297",
   "metadata": {},
   "source": [
    "## 2) Setup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "10fd98b3",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import json\n",
    "import re\n",
    "import shutil\n",
    "\n",
    "from datetime import datetime\n",
    "from openai import OpenAI, AsyncOpenAI\n",
    "from agents import Agent, Runner, OpenAIResponsesModel, function_tool\n",
    "\n",
    "import os\n",
    "os.environ[\"OPENAI_API_KEY\"] = \"\"  # your skey\n",
    "\n",
    "client = OpenAI(api_key=os.getenv(\"OPENAI_API_KEY\"))\n",
    "gpt_async_client = AsyncOpenAI(api_key=os.getenv(\"OPENAI_API_KEY\"))\n",
    "\n",
    "# Open-model endpoint settings (for vLLM/Ollama/OpenRouter-compatible APIs)\n",
    "OPEN_MODEL_BASE_URL = os.getenv(\"OPEN_MODEL_BASE_URL\", \"http://localhost:8000/v1\")\n",
    "OPEN_MODEL_API_KEY = os.getenv(\"OPEN_MODEL_API_KEY\", \"EMPTY\")\n",
    "open_async_client = AsyncOpenAI(base_url=OPEN_MODEL_BASE_URL, api_key=OPEN_MODEL_API_KEY)\n",
    "\n",
    "# Hosted embedding endpoint (e.g., vLLM --task embed)\n",
    "EMBED_BASE_URL = os.getenv(\"EMBED_BASE_URL\", \"http://localhost:8001/v1\")\n",
    "EMBED_API_KEY = os.getenv(\"EMBED_API_KEY\", \"EMPTY\")\n",
    "emb_client = OpenAI(base_url=EMBED_BASE_URL, api_key=EMBED_API_KEY)\n",
    "\n",
    "MODEL_GPT = \"gpt-4.1-mini\"\n",
    "MODEL_OPEN = os.getenv(\"OPEN_MODEL\", \"qwen3-4b-instruct\")\n",
    "ACTIVE_PROVIDER = os.getenv(\"ACTIVE_PROVIDER\", \"gpt\")  # set to 'open' to use qwen/open model\n",
    "MODEL = MODEL_GPT\n",
    "EMBED_MODEL = os.getenv(\"EMBED_MODEL\", \"BAAI/bge-m3\")\n",
    "\n",
    "if not os.getenv(\"OPENAI_API_KEY\"):\n",
    "    raise ValueError(\"OPENAI_API_KEY is not set. Put it in env or .env file.\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f2e0c6a4",
   "metadata": {},
   "source": [
    "## 2.5) Start vLLM Servers in Notebook (Optional)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f0aa2b0d",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Run these in the command\n",
    "\n",
    "# pip install vllm\n",
    "# python -c \"import sys; print(sys.executable)\"\n",
    "# python -c \"import vllm; print(vllm.__version__)\"\n",
    "# nohup \"$(python -c 'import sys; print(sys.executable)')\" -m vllm.entrypoints.openai.api_server --model Qwen/Qwen3-4B-Instruct --host 127.0.0.1 --port 8000 > /tmp/vllm_llm.log 2>&1 &\n",
    "# nohup \"$(python -c 'import sys; print(sys.executable)')\" -m vllm.entrypoints.openai.api_server --model BAAI/bge-m3 --task embed --host 127.0.0.1 --port 8001 > /tmp/vllm_emb.log 2>&1 &\n",
    "# sleep 5\n",
    "# tail -n 80 /tmp/vllm_llm.log\n",
    "# tail -n 80 /tmp/vllm_emb.log"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7fce0faa-9d31-43a8-9d22-ba963bb7fb3d",
   "metadata": {},
   "source": [
    "## 3) Helper"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "f8876cf1",
   "metadata": {},
   "outputs": [],
   "source": [
    "async def run_agent(agent_name, instructions, user_input, model=None, provider=\"gpt\", tools=None):\n",
    "    if provider == \"gpt\":\n",
    "        selected_model = model or MODEL_GPT\n",
    "        model_obj = OpenAIResponsesModel(selected_model, gpt_async_client)\n",
    "    elif provider == \"open\":\n",
    "        selected_model = model or MODEL_OPEN\n",
    "        model_obj = OpenAIResponsesModel(selected_model, open_async_client)\n",
    "    else:\n",
    "        raise ValueError(\"provider must be 'gpt' or 'open'\")\n",
    "\n",
    "    agent = Agent(\n",
    "        name=agent_name,\n",
    "        instructions=instructions,\n",
    "        model=model_obj,\n",
    "        tools=tools or [],\n",
    "    )\n",
    "    result = await Runner.run(agent, user_input)\n",
    "    return result.final_output, result\n",
    "\n",
    "async def ask(messages_or_text, model=None, provider=\"gpt\", temperature=0):\n",
    "    if isinstance(messages_or_text, list):\n",
    "        text_parts = []\n",
    "        for m in messages_or_text:\n",
    "            content = m.get(\"content\", \"\") if isinstance(m, dict) else str(m)\n",
    "            text_parts.append(str(content))\n",
    "        user_input = \"\\n\".join([x for x in text_parts if x])\n",
    "    else:\n",
    "        user_input = messages_or_text\n",
    "    return await run_agent(\"Assistant\", \"\", user_input, model=model, provider=provider)\n",
    "\n",
    "def embed_texts(texts):\n",
    "    emb = emb_client.embeddings.create(model=EMBED_MODEL, input=texts)\n",
    "    return [item.embedding for item in emb.data]\n",
    "\n",
    "\n",
    "def extract_json_object(text):\n",
    "    m = re.search(r\"\\{[\\s\\S]*\\}\", text)\n",
    "    if not m:\n",
    "        raise ValueError(\"No JSON object found in output:\\n\" + text)\n",
    "    return json.loads(m.group(0))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d7760764",
   "metadata": {},
   "source": [
    "## 4) Tool Demo (Without Tool vs With Tool)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "b75d5e35",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "WITHOUT TOOL: Today is 2024-04-27, Saturday.\n",
      "The agent is calling this tool!\n",
      "WITH TOOL: Today is 2026-02-13, and the weekday is Friday.\n"
     ]
    }
   ],
   "source": [
    "@function_tool\n",
    "def get_current_date() -> dict:\n",
    "    now = datetime.now()\n",
    "    print(\"The agent is calling this tool!\")\n",
    "    return {\"date\": now.strftime(\"%Y-%m-%d\"), \"weekday\": now.strftime(\"%A\")}\n",
    "\n",
    "q = \"What day is today? Return exact date as YYYY-MM-DD and weekday.\"\n",
    "without_tool, _ = await ask([{\"role\": \"user\", \"content\": q}], provider=ACTIVE_PROVIDER)\n",
    "print(\"WITHOUT TOOL:\", without_tool)\n",
    "\n",
    "\n",
    "with_tool, _ = await run_agent(\n",
    "    \"Tool Agent\",\n",
    "    \"Use get_current_date when user asks about current date or weekday.\",\n",
    "    q,\n",
    "    provider=ACTIVE_PROVIDER,\n",
    "    tools=[get_current_date],\n",
    ")\n",
    "\n",
    "print(\"WITH TOOL:\", with_tool)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b17a31a8",
   "metadata": {},
   "source": [
    "## 5) Memory Demo with Vector Database (Without Memory vs With Vector Memory)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "174ee373-0cd5-43f6-a21e-043591214b4b",
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "import faiss\n",
    "\n",
    "# 1) init in-memory FAISS index + record store\n",
    "records = []\n",
    "index = None\n",
    "\n",
    "# 2) write one fact\n",
    "record = {\n",
    "    \"id\": \"fact_jeff_birthday\",\n",
    "    \"text\": \"Jeff's birthday is February 1.\",\n",
    "    \"metadata\": {\"type\": \"birthday\", \"person\": \"Jeff\"},\n",
    "}\n",
    "vec = embed_texts([record[\"text\"]])[0]\n",
    "x = np.array([vec], dtype=\"float32\")\n",
    "faiss.normalize_L2(x)\n",
    "index = faiss.IndexFlatIP(x.shape[1])\n",
    "index.add(x)\n",
    "records.append(record)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "41653764",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "WITHOUT MEMORY: I don't know when Jeff's birthday is.\n"
     ]
    }
   ],
   "source": [
    "# 3) ask without memory\n",
    "q = \"When is Jeff's birthday?\"\n",
    "without_memory, _ = await run_agent(\n",
    "    \"QA Agent\",\n",
    "    \"Answer from your own knowledge. If unsure, say you don't know.\",\n",
    "    q,\n",
    "    provider=ACTIVE_PROVIDER,\n",
    ")\n",
    "print(\"WITHOUT MEMORY:\", without_memory)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "1bcb1e6f-fadf-4601-9974-5dd9e4cc6502",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "WITH MEMORY: Jeff's birthday is February 1.\n"
     ]
    }
   ],
   "source": [
    "# 4) retrieve + ask with memory\n",
    "qvec = np.array([embed_texts([q])[0]], dtype=\"float32\")\n",
    "faiss.normalize_L2(qvec)\n",
    "k = min(1, len(records))\n",
    "\n",
    "docs = []\n",
    "if index is not None and k > 0:\n",
    "    _, I = index.search(qvec, k)\n",
    "    docs = [records[i][\"text\"] for i in I[0] if i >= 0]\n",
    "ctx = \"\\n\".join(f\"- {d}\" for d in docs)\n",
    "\n",
    "with_memory, _ = await run_agent(\n",
    "    \"Memory Agent\",\n",
    "    f\"Use retrieved facts to answer.\\nRetrieved facts:\\n{ctx}\",\n",
    "    q,\n",
    "    provider=ACTIVE_PROVIDER,\n",
    ")\n",
    "print(\"WITH MEMORY:\", with_memory)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "15f516e3",
   "metadata": {},
   "source": [
    "## 6) Planning Demo: Same Prompt, Different Agent Policy\n",
    "\n",
    "We use the **same user task** and compare:\n",
    "- Direct Agent: one-shot answer\n",
    "- Planning Agent: Planner -> Executor -> Final"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "9441fc3a",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== SAME TASK ===\n",
      "Compare GLP-1 receptor agonists vs SGLT2 inhibitors in adults with type 2 diabetes.\n",
      "\n",
      "=== DIRECT AGENT (WITHOUT PLANNING) ===\n",
      "Certainly! Here's a comparison of **GLP-1 receptor agonists (GLP-1 RAs)** and **SGLT2 inhibitors** in adults with type 2 diabetes, focusing on mechanism, efficacy, benefits, side effects, and other clinical considerations:\n",
      "\n",
      "---\n",
      "\n",
      "### 1. **Mechanism of Action**\n",
      "\n",
      "- **GLP-1 Receptor Agonists:**  \n",
      "  Mimic the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon secretion, slowing gastric emptying, and increasing satiety.\n",
      "\n",
      "- **SGLT2 Inhibitors:**  \n",
      "  Inhibit sodium-glucose co-transporter 2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion.\n",
      "\n",
      "---\n",
      "\n",
      "### 2. **Glycemic Control**\n",
      "\n",
      "- **GLP-1 RAs:**  \n",
      "  Typically lower HbA1c by approximately 1.0–1.5%. Particularly effective in reducing postprandial glucose.\n",
      "\n",
      "- **SGLT2 Inhibitors:**  \n",
      "  Lower HbA1c by about 0.5–1.0%. More effective for lowering fasting glucose.\n",
      "\n",
      "---\n",
      "\n",
      "### 3. **Weight Effects**\n",
      "\n",
      "- **GLP-1 RAs:**  \n",
      "  Promote significant weight loss, often 2–5 kg or more, due to appetite suppression and delayed gastric emptying.\n",
      "\n",
      "- **SGLT2 Inhibitors:**  \n",
      "  Moderate weight loss (~2–3 kg), primarily from loss of calories through glucosuria and mild diuresis.\n",
      "\n",
      "---\n",
      "\n",
      "### 4. **Cardiovascular Benefits**\n",
      "\n",
      "- **GLP-1 RAs:**  \n",
      "  Show clear reductions in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease (e.g., liraglutide, semaglutide).\n",
      "\n",
      "- **SGLT2 Inhibitors:**  \n",
      "  Reduce MACE and have strong benefits in reducing heart failure hospitalization and cardiovascular death, even in patients with or without established cardiovascular disease.\n",
      "\n",
      "---\n",
      "\n",
      "### 5. **Renal Effects**\n",
      "\n",
      "- **GLP-1 RAs:**  \n",
      "  Modest renal benefits primarily through reduction of albuminuria, with ongoing research about impact on progression of diabetic kidney disease.\n",
      "\n",
      "- **SGLT2 Inhibitors:**  \n",
      "  Demonstrated significant renal protection, slowing progression of diabetic nephropathy and reducing risk of kidney failure.\n",
      "\n",
      "---\n",
      "\n",
      "### 6. **Side Effects**\n",
      "\n",
      "- **GLP-1 RAs:**  \n",
      "  Nausea, vomiting, diarrhea; risk of pancreatitis (rare); injection-site reactions; possible contraindications in patients with history of medullary thyroid carcinoma or MEN2.\n",
      "\n",
      "- **SGLT2 Inhibitors:**  \n",
      "  Genital mycotic infections, urinary tract infections, volume depletion/hypotension, diabetic ketoacidosis (euglycemic DKA), risk of fractures and amputations (with some agents).\n",
      "\n",
      "---\n",
      "\n",
      "### 7. **Route of Administration**\n",
      "\n",
      "- **GLP-1 RAs:**  \n",
      "  Mostly subcutaneous injection (daily, weekly formulations) though oral semaglutide is available.\n",
      "\n",
      "- **SGLT2 Inhibitors:**  \n",
      "  Oral tablets.\n",
      "\n",
      "---\n",
      "\n",
      "### 8. **Additional Clinical Considerations**\n",
      "\n",
      "- GLP-1 RAs can be preferred when weight loss is a priority and when there is a need to reduce appetite.  \n",
      "- SGLT2 inhibitors are especially preferred in patients with heart failure or chronic kidney disease due to robust benefits in these conditions.  \n",
      "- Both classes can be used in combination for additive benefits.\n",
      "\n",
      "---\n",
      "\n",
      "### Summary Table:\n",
      "\n",
      "| Feature                  | GLP-1 Receptor Agonists             | SGLT2 Inhibitors                   |\n",
      "|--------------------------|-----------------------------------|----------------------------------|\n",
      "| Mechanism                | Enhances insulin secretion, slows gastric emptying | Inhibits renal glucose reabsorption |\n",
      "| HbA1c reduction          | ~1.0–1.5%                        | ~0.5–1.0%                       |\n",
      "| Weight change            | Significant weight loss           | Moderate weight loss             |\n",
      "| Cardiovascular benefits  | Reduces MACE                     | Reduces MACE, heart failure hospitalization |\n",
      "| Renal benefits           | Modest                         | Significant                     |\n",
      "| Common side effects      | GI upset (nausea), injection site reactions  | Genital infections, volume depletion |\n",
      "| Administration           | Injectable (mostly), oral option available | Oral                           |\n",
      "\n",
      "---\n",
      "\n",
      "If you want, I can provide more detailed guidance on use in specific clinical scenarios!\n"
     ]
    }
   ],
   "source": [
    "TASK = \"Compare GLP-1 receptor agonists vs SGLT2 inhibitors in adults with type 2 diabetes.\"\n",
    "\n",
    "\n",
    "async def direct_agent(task, provider=\"gpt\", model=None):\n",
    "    ans, _ = await ask([{\"role\": \"user\", \"content\": task}], temperature=0, provider=provider, model=model)\n",
    "    return ans\n",
    "\n",
    "\n",
    "async def planning_agent(task, provider=\"gpt\", model=None):\n",
    "    planner_prompt = (\n",
    "        \"You are Biomedical Research Planner.\\n\"\n",
    "        \"Return strict JSON only with this schema:\\n\"\n",
    "        \"{\\n\"\n",
    "        \"  \\\"goal\\\": \\\"...\\\",\\n\"\n",
    "        \"  \\\"scope\\\": {\\\"population\\\": \\\"...\\\", \\\"interventions\\\": [\\\"...\\\"], \\\"outcomes\\\": [\\\"...\\\"]},\\n\"\n",
    "        \"  \\\"steps\\\": [\\n\"\n",
    "        \"    {\\\"id\\\": 1, \\\"task\\\": \\\"...\\\", \\\"done_definition\\\": \\\"...\\\"}\\n\"\n",
    "        \"  ]\\n\"\n",
    "        \"}\\n\"\n",
    "        f\"Task: {task}\"\n",
    "    )\n",
    "\n",
    "    plan_text, _ = await ask(planner_prompt, temperature=0, provider=provider, model=model)\n",
    "    plan = extract_json_object(plan_text)\n",
    "\n",
    "    step_results = []\n",
    "    for s in plan[\"steps\"]:\n",
    "        exec_prompt = (\n",
    "            \"You are Biomedical Research Executor.\\n\"\n",
    "            f\"Goal: {plan['goal']}\\n\"\n",
    "            f\"Scope: {json.dumps(plan['scope'])}\\n\"\n",
    "            f\"Step: {s['task']}\\n\"\n",
    "            f\"Done definition: {s['done_definition']}\\n\"\n",
    "            \"Provide concise but evidence-oriented output for this step.\"\n",
    "        )\n",
    "        out, _ = await ask(exec_prompt, temperature=0, provider=provider, model=model)\n",
    "        step_results.append({\"id\": s[\"id\"], \"task\": s[\"task\"], \"result\": out})\n",
    "\n",
    "    final_prompt = (\n",
    "        \"You are Biomedical Finalizer.\\n\"\n",
    "        \"Produce a deep-research style report with:\\n\"\n",
    "        \"1) clinical question framing (PICO)\\n\"\n",
    "        \"2) evidence synthesis table (benefits/risks)\\n\"\n",
    "        \"3) subgroup considerations (CKD, obesity, elderly)\\n\"\n",
    "        \"4) practical prescribing recommendations\\n\"\n",
    "        \"5) uncertainty and evidence gaps\\n\"\n",
    "        f\"Task: {task}\\n\"\n",
    "        f\"Plan: {json.dumps(plan, ensure_ascii=False)}\\n\"\n",
    "        f\"Step results: {json.dumps(step_results, ensure_ascii=False)}\"\n",
    "    )\n",
    "    final_text, _ = await ask(final_prompt, temperature=0, provider=provider, model=model)\n",
    "\n",
    "    return {\n",
    "        \"plan\": plan,\n",
    "        \"step_results\": step_results,\n",
    "        \"final\": final_text,\n",
    "    }\n",
    "\n",
    "baseline = await direct_agent(TASK, provider=ACTIVE_PROVIDER)\n",
    "print(\"=== SAME TASK ===\")\n",
    "print(TASK)\n",
    "print(\"\\n=== DIRECT AGENT (WITHOUT PLANNING) ===\")\n",
    "print(baseline)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "9480ff6b-4222-4df2-9bf6-edc03b441fa9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "=== PLANNING AGENT (WITH PLANNING) - FINAL ===\n",
      "**Comparative Effectiveness and Safety of GLP-1 Receptor Agonists vs SGLT2 Inhibitors in Adults with Type 2 Diabetes: A Deep-Research Report**\n",
      "\n",
      "---\n",
      "\n",
      "### 1) Clinical Question Framing (PICO)\n",
      "\n",
      "| Element        | Description                                                                                                               |\n",
      "|----------------|---------------------------------------------------------------------------------------------------------------------------|\n",
      "| **Population** | Adults diagnosed with type 2 diabetes mellitus (T2DM), including those with or without established cardiovascular (CV) or renal disease. |\n",
      "| **Interventions** | GLP-1 receptor agonists (liraglutide, semaglutide, exenatide, dulaglutide, and others)                                   |\n",
      "| **Comparator** | SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, and others)                                                |\n",
      "| **Outcomes**   | - Glycemic control (HbA1c reduction) <br> - Weight change <br> - Cardiovascular outcomes (MACE, heart failure hospitalization) <br> - Renal outcomes (progression of nephropathy, eGFR decline) <br> - Adverse events (AEs) <br> - All-cause mortality |\n",
      "\n",
      "**Clinical Question:**  \n",
      "In adults with type 2 diabetes, how do GLP-1 receptor agonists compare to SGLT2 inhibitors in terms of glycemic efficacy, weight change, cardiovascular and renal outcomes, safety, and mortality?\n",
      "\n",
      "---\n",
      "\n",
      "### 2) Evidence Synthesis Table (Benefits / Risks)\n",
      "\n",
      "| Outcome                  | GLP-1 Receptor Agonists                            | SGLT2 Inhibitors                                   | Comparative Notes                          |\n",
      "|--------------------------|---------------------------------------------------|---------------------------------------------------|--------------------------------------------|\n",
      "| **Glycemic Control (HbA1c reduction)**  | ~1.0–1.5% reduction; greater than SGLT2i (mean difference -0.25%, 95% CI: -0.35 to -0.15)   | ~0.7–1.0% reduction                               | GLP-1 RAs superior by ~0.25% HbA1c          |\n",
      "| **Weight Change**          | ~2–4 kg weight loss; generally greater reduction | ~1.5–3 kg weight loss                              | GLP-1 RAs provide greater weight loss (-1.8 kg difference favoring GLP-1 RAs) |\n",
      "| **Cardiovascular Outcomes** (MACE)       | HR ~0.87 vs placebo; reduces atherosclerotic events          | HR ~0.86–0.89 vs placebo; superior in reducing heart failure hospitalization | Similar MACE reduction; SGLT2is stronger on HF events |\n",
      "| **Renal Outcomes**         | Modest renal protection; HR ~0.8–0.85 for nephropathy progression | Strong renal protection; HR ~0.6 for nephropathy progression | SGLT2 inhibitors superior in slowing renal decline |\n",
      "| **Adverse Events**         | Mainly GI side effects (nausea, vomiting); risk of pancreatitis unclear | Genital mycotic infections, volume depletion, rare DKA | Different safety profiles; manageable with counseling |\n",
      "| **All-Cause Mortality**    | Reduced risk vs placebo; HR ~0.85                 | Reduced risk vs placebo; may show somewhat greater mortality benefit; HR ~0.68–0.70 | Mortality benefits comparable, possibly greater with SGLT2i |\n",
      "\n",
      "---\n",
      "\n",
      "### 3) Subgroup Considerations\n",
      "\n",
      "| Subgroup        | GLP-1 Receptor Agonists                      | SGLT2 Inhibitors                              | Clinical Implications                         |\n",
      "|-----------------|----------------------------------------------|-----------------------------------------------|-----------------------------------------------|\n",
      "| **Chronic Kidney Disease (CKD)** | Safe to use with mild-to-moderate CKD; modest renal benefits; efficacy maintained | Superior renal protection; recommended down to eGFR 30 mL/min/1.73m² or lower (varies by agent) | Prefer SGLT2i for CKD and kidney protection; GLP-1 RA second line if SGLT2i contraindicated or intolerant |\n",
      "| **Obesity**      | Greater weight loss, appetite suppression beneficial | Moderate weight loss, osmotic diuresis mechanism | GLP-1 RAs preferred if weight loss is primary goal |\n",
      "| **Elderly (>65 years)** | Effective and generally well tolerated; GI side effects may limit use in frail elderly | Effective; cautious use due to volume depletion, hypotension risk | Individualize based on frailty, risk of dehydration, and side effect profiles |\n",
      "\n",
      "---\n",
      "\n",
      "### 4) Practical Prescribing Recommendations\n",
      "\n",
      "- **Choose GLP-1 RAs when:**\n",
      "  - Greater HbA1c lowering needed.\n",
      "  - Weight loss is a high priority (especially obesity).\n",
      "  - Patient tolerates injectable therapy (most GLP-1 RAs are injectable; oral semaglutide is an option).\n",
      "  - Primary indication is reduction of atherosclerotic CV events.\n",
      "  - Caution in CKD stages 4–5 or dialysis (depending on agent approval).\n",
      "\n",
      "- **Choose SGLT2 inhibitors when:**\n",
      "  - Patient has established heart failure (esp. reduced ejection fraction).\n",
      "  - Diabetic kidney disease is present or at risk (eGFR permissive).\n",
      "  - Oral administration preferred.\n",
      "  - Patient has volume tolerance; avoid in risk for hypotension or frequent UTIs/genital infections.\n",
      "  \n",
      "- **Combination therapy** is a rational consideration to leverage complementary benefits (better glycemic control, weight loss, heart failure, and renal protection), but consider cost, complexity, and adherence.\n",
      "\n",
      "- **Monitoring and counseling:**\n",
      "  - GLP-1 RAs: Monitor for GI tolerance; educate regarding nausea mitigation strategies.\n",
      "  - SGLT2 inhibitors: Counsel on genital hygiene, monitor volume status, educate on signs of ketoacidosis.\n",
      "  \n",
      "- **Dose adjustments:**\n",
      "  - Renal function-guided dosing especially important for SGLT2is.\n",
      "  - Consider titration schedules with GLP-1 RAs to minimize GI side effects.\n",
      "\n",
      "---\n",
      "\n",
      "### 5) Uncertainty and Evidence Gaps\n",
      "\n",
      "- **Head-to-head RCTs directly comparing GLP-1 RAs vs SGLT2is**: Limited data; most comparative evidence arises from indirect meta-analyses or trials vs placebo.\n",
      "- **Long-term safety and durability data:** Both classes are relatively new; data beyond 3–5 years remain limited.\n",
      "- **Elderly and frail populations:** Underrepresented in trials; safety and efficacy in very old or multi-morbid patients need further research.\n",
      "- **Combination therapy trials:** More robust evidence on combined GLP-1 RA plus SGLT2i in diverse populations is needed.\n",
      "- **Heterogeneity of responses:** Pharmacogenomic and phenotypic predictors of best response to each class are insufficiently characterized.\n",
      "- **Cost-effectiveness and access:** Real-world evidence evaluating economic impact and patient adherence challenges is sparse.\n",
      "- **Rare and serious adverse events:** Continued pharmacovigilance needed, especially concerning pancreatitis with GLP-1 RAs and diabetic ketoacidosis with SGLT2is.\n",
      "\n",
      "---\n",
      "\n",
      "### **Summary**\n",
      "\n",
      "- GLP-1 receptor agonists provide superior glycemic control and weight loss, with robust CV risk reduction focused on atherosclerotic events but moderate renal benefit. They are often injectable and have prominent GI side effects.\n",
      "- SGLT2 inhibitors offer strong renal protection and heart failure benefits, with moderate glycemic and weight benefits, administered orally but with risks of genital infections and hypovolemia.\n",
      "- Treatment selection should be individualized based on patient comorbidities (CKD, heart failure), weight goals, tolerability, route preference, and risk profiles.\n",
      "- Both classes reduce mortality and cardiovascular morbidity and can be complementary when combined.\n",
      "- More direct comparative research and long-term data are needed to refine optimal clinical use.\n",
      "\n",
      "---\n",
      "\n",
      "**Prepared by:** Biomedical Finalizer  \n",
      "**Date:** June 2024\n"
     ]
    }
   ],
   "source": [
    "planned = await planning_agent(TASK, provider=ACTIVE_PROVIDER)\n",
    "print(\"\\n=== PLANNING AGENT (WITH PLANNING) - FINAL ===\")\n",
    "print(planned[\"final\"])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7756fe61",
   "metadata": {},
   "source": [
    "## 7) Optional: Quick scorecard"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "70b24749",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DIRECT score: 4 {'cardiovascular': True, 'renal': True, 'weight': True, 'safety': True, 'cost_access': False}\n",
      "PLANNED score: 5 {'cardiovascular': True, 'renal': True, 'weight': True, 'safety': True, 'cost_access': True}\n"
     ]
    }
   ],
   "source": [
    "def simple_score(text):\n",
    "    t = text.lower()\n",
    "    checks = {\n",
    "        \"cardiovascular\": any(k in t for k in [\"cardiovascular\", \"cv\", \"mace\", \"heart failure\"]),\n",
    "        \"renal\": any(k in t for k in [\"renal\", \"kidney\", \"ckd\", \"egfr\", \"albuminuria\"]),\n",
    "        \"weight\": any(k in t for k in [\"weight\", \"obesity\", \"bmi\"]),\n",
    "        \"safety\": any(k in t for k in [\"safety\", \"adverse\", \"side effect\", \"risk\"]),\n",
    "        \"cost_access\": any(k in t for k in [\"cost\", \"access\", \"insurance\", \"affordability\"]),\n",
    "    }\n",
    "    return sum(int(v) for v in checks.values()), checks\n",
    "\n",
    "s1, c1 = simple_score(baseline)\n",
    "s2, c2 = simple_score(planned[\"final\"])\n",
    "print(\"DIRECT score:\", s1, c1)\n",
    "print(\"PLANNED score:\", s2, c2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "94289f2a-e9fa-484d-9bb0-7dc79a99e45f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The Planning Agent output is stronger overall for this task.\n",
      "\n",
      "It is better structured, more comprehensive, and much closer to a true deep-research deliverable. It covers key clinical dimensions (CV, renal, weight, safety, subgroup use, and practical prescribing) and presents them in a decision-friendly format. By contrast, the Direct Agent response is clear and accurate at a high level, but it is more of a concise overview than a research-grade synthesis.\n",
      "\n",
      "The main caveat is verification: the Planning version includes quantitative claims and citations that should be independently checked before clinical or publication use.\n"
     ]
    }
   ],
   "source": [
    "print(\"\"\"The Planning Agent output is stronger overall for this task.\n",
    "\n",
    "It is better structured, more comprehensive, and much closer to a true deep-research deliverable. It covers key clinical dimensions (CV, renal, weight, safety, subgroup use, and practical prescribing) and presents them in a decision-friendly format. By contrast, the Direct Agent response is clear and accurate at a high level, but it is more of a concise overview than a research-grade synthesis.\n",
    "\n",
    "The main caveat is verification: the Planning version includes quantitative claims and citations that should be independently checked before clinical or publication use.\"\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "988f6337-9f2a-4c31-84ae-590c0aa5e84a",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "finben",
   "language": "python",
   "name": "finben"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
